What is DxTerity?
DxTerity is a pioneering entity in the precision medicine landscape, specializing in RNA-based diagnostics tailored for autoimmune diseases. The company's core innovation lies in its ability to offer precision testing that provides deeper insights into the biological mechanisms driving these complex conditions. By focusing on the genetic and molecular factors, DxTerity equips healthcare professionals with advanced tools for more accurate diagnoses and personalized treatment strategies. Their commitment extends to making cutting-edge precision medicine accessible and affordable through patented technologies and a focus on at-home genomic monitoring, thereby enhancing patient well-being and advancing the understanding of autoimmune diseases through ongoing clinical studies.
How much funding has DxTerity raised?
DxTerity has raised a total of $4.5M across 4 funding rounds:
Private Equity
$790K
Debt
$2.6M
Debt
$350K
Debt
$794K
Private Equity (2009): $790K, investors not publicly disclosed
Debt (2012): $2.6M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Debt (2021): $794K featuring PPP
What's next for DxTerity?
With the recent influx of major strategic investment and substantial enterprise-level funding, DxTerity is poised for accelerated growth and expanded market penetration. The company's focus on developing and deploying advanced RNA-based diagnostics for autoimmune diseases aligns with the increasing demand for personalized healthcare solutions. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the reach of their innovative testing platforms. DxTerity's strategic direction likely involves strengthening its position as a leader in precision diagnostics, potentially exploring new therapeutic areas, and forging key partnerships within the healthcare ecosystem to further its mission of improving patient outcomes through accessible, low-cost genomic monitoring.
See full DxTerity company page
